T1	p 176 182	asthma
T2	p 246 291	patients with asthma poorly controlled on low
T3	p 691 709	adult asthmatics .
T4	p 718 741	Sixty-six subjects were
T5	i 6 91	Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast
T6	i 305 320	corticosteroids
T7	i 433 451	placebo-controlled
T8	i 504 568	salmeterol plus fluticasone propionate ( FP ) ( Seretide ; SFC )
T9	i 573 599	FP plus montelukast ( FP/M
T10	i 756 767	SFC or FP/M
T11	i 1379 1383	FP/M
T12	i 1386 1390	FP/M
T13	o 142 172	effects on airway inflammation
T14	o 388 409	airway inflammation .
T15	o 605 687	sputum inflammatory markers , airway responsiveness , lung function , and symptoms
T16	o 818 916	neutrophil , eosinophil , macrophage , lymphocyte , and epithelial cell levels in induced sputum .
T17	o 950 1067	change in other sputum markers of airway inflammation , airway responsiveness , symptom control , and lung function .
T18	o 1129 1154	sputum inflammatory cells
T19	o 1200 1223	in sputum eosinophils .
T20	o 1263 1284	airway responsiveness
T21	o 1340 1373	symptom control and lung function
T22	o 1420 1463	reductions in sputum cysteinyl leukotrienes
T23	o 1575 1607	eosinophilic airway inflammation
T24	o 1627 1634	symptom